The price-to-earnings ratio for Novo Nordisk ADR (NYSE: NVO) is 41.36x, which is above its average ratio. Moreover, the 36-month beta value for NVO is 0.38.

The average price recommended by analysts for Novo Nordisk ADR (NVO) is $103.26, which is $3.73 above the current market price. The public float for NVO is 3.37B and currently, short sellers hold a 0.13% of that float. On November 17, 2023, NVO’s average trading volume was 4.58M shares.

Elon Musk just Triggered a BOOM in These Stocks

Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk. Get your copy of "Top 5 Tech Stocks to Buy in 2024"

Click Here to Download the FREE Report.


NVO) stock’s latest price update

Novo Nordisk ADR (NYSE: NVO)’s stock price has soared by 3.21 in relation to previous closing price of 96.43. Nevertheless, the company has seen a loss of -0.50% in its stock price over the last five trading days. Zacks Investment Research reported 2023-11-16 that What do stretchy pants, fat-loss drugs, and sports betting have in common? Each of these is powering some of the strongest mega-trends on Wall Street.

NVO’s Market Performance

NVO’s stock has fallen by -0.50% in the past week, with a monthly drop of -1.03% and a quarterly rise of 8.70%. The volatility ratio for the week is 2.60% while the volatility levels for the last 30 days are 2.10% for Novo Nordisk ADR. The simple moving average for the past 20 days is 1.22% for NVO’s stock, with a 18.21% simple moving average for the past 200 days.

Analysts’ Opinion of NVO

Many brokerage firms have already submitted their reports for NVO stocks, with Argus repeating the rating for NVO by listing it as a “Buy.” The predicted price for NVO in the upcoming period, according to Argus is $110 based on the research report published on October 02, 2023 of the current year 2023.

NVO Trading at 3.48% from the 50-Day Moving Average

After a stumble in the market that brought NVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.30% of loss for the given period.

Volatility was left at 2.10%, however, over the last 30 days, the volatility rate increased by 2.60%, as shares surge +1.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.88% upper at present.

During the last 5 trading sessions, NVO fell by -0.50%, which changed the moving average for the period of 200-days by +43.13% in comparison to the 20-day moving average, which settled at $98.43. In addition, Novo Nordisk ADR saw 47.08% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for NVO

Current profitability levels for the company are sitting at:

The net margin for Novo Nordisk ADR stands at +31.38. The total capital return value is set at 72.02, while invested capital returns managed to touch 57.99. Equity return is now at value 93.02, with 29.06 for asset returns.

Based on Novo Nordisk ADR (NVO), the company’s capital structure generated 30.88 points at debt to equity in total, while total debt to capital is 23.60. Total debt to assets is 10.69, with long-term debt to equity ratio resting at 29.13. Finally, the long-term debt to capital ratio is 22.25.

When we switch over and look at the enterprise to sales, we see a ratio of 12.30, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 3.79 and the total asset turnover is 0.81. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.89.


To wrap up, the performance of Novo Nordisk ADR (NVO) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.